BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Misinterpretations and Mistakes Portrayed by Hollywood in the General set of laws - 2Vote In favor of Your Favored Web based Dating Application
- 3Scientists sent a menstrual cup to space. This is how it went
- 4Explainer-Why are hepatitis B vaccines given to newborns?
- 5Deadly heat worldwide prompts $300 million for climate health research at COP30
- This Week In Space podcast: Episode 188 — A New NASA Leader Rises?
- My Enterprising Excursion: Building a Startup
- 10 Hints for an Effective New employee screening
- Kidneys from Black donors are more likely to be thrown away − a bioethicist explains why
- U.S. to drop childhood vaccine recommendations as it looks to Denmark, Washington Post reports
- America's Confided in Cooler in 2024
- Why the chemtrail conspiracy theory lingers and grows – and why Tucker Carlson is talking about it
- Ukraine proved this drone-killer works. Now, the West is giving it a shot.
- Find Exemplary Scents: An Extensive Aide
